Aurobindo Pharma Limited has informed the Exchange about Action(s) taken or orders passed by CESTAT, Chennai.

Litigation lossRegulatory & Legal View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹1161.90

prior close

₹1161.90

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+1.0%-1.2% vs market

Pharmaceuticals peers, median of 151sector+0.5%-0.7% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Midcap 150 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.3

15m

+0.7

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2+1.0-1.2+0.5-0.7

Next day

+0.6+1.0-0.4+1.1-0.5

+0.4+0.7-0.3+1.6-1.2

-0.8-0.8+0.1+1.5-2.2

-1.2-1.2-0.0+1.0-2.2

-1.7-0.4-1.2+0.7-2.4

-5.0-1.5-3.5-1.3-3.7

15d

-2.5+1.4-3.9-0.2-2.3

-1.6+0.9-2.5-0.4-1.3

-9.6-3.2-6.3-2.9-6.7

-9.8-1.8-8.0-2.2-7.6

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma received an order from CESTAT Chennai on June 6, 2025, dismissing its appeal against a 2015 Customs Commissioner order. The original dispute relates to alleged non-fulfilment of export obligations under two Advance Authorizations. The total disputed amount is Customs Duty of about Rs. 29.17 lakhs, a redemption fine of Rs. 50 lakhs, and a penalty of Rs. 10 lakhs, along with applicable interest. The company argued that there was only a delay in fulfilling export obligations and that it had sought an extension from the Director General Foreign Trade. The company plans to file a further appeal in the High Court against the CESTAT order. The company has stated that there is no material impact on its financials or operations from this order.

Likely market impact

This is a minor legal setback for Aurobindo Pharma, but the company says the financial impact is not material given the relatively small disputed amount (under Rs. 1 crore total). Shareholders are unlikely to see any meaningful effect on the stock, though the upcoming High Court appeal will be worth watching.